SCOTTSDALE, Ariz. - Rowpar Pharmaceuticals, Inc., the makers of the ClōSYS brand of toothpastes, mouthwashes and oral sprays, announced today that an in vitro laboratory analysis showed that ClōSYS Ultra Sensitive Oral Rinse reduced the Influenza A H3N2 virus up to 99.993% within 30 seconds without the use of any harsh chemicals. The lab study findings (which did not include testing in the oral cavity) are particularly important because flu seasons during which Influenza A H3N2 is the dominant virus tend to be more severe, recent history shows.
Rowpar recently announced that an in vitro laboratory analysis showed that ClōSYS Ultra Sensitive Oral Rinse reduced SARS-CoV-2 (COVID-19 virus) up to 98.4% within 30 seconds (CloSYS.com/covid). Those initial lab tests did not include testing in the oral cavity, but based on the results, Rowpar has launched clinical studies to determine whether ClōSYS over-the-counter products can help lower the transmission of the novel coronavirus from one person to another.
“Because oral health is known to impact whole body health, self-care is more important than ever, especially during a pandemic,” said CEO of Rowpar Pharmaceuticals Jim Ratcliff. “These initial findings on Influenza A, together with the COVID-19 results, are extremely encouraging. We’re pleased to be able to share them now, as we head into a particularly uncertain flu and cold season and a possible ‘twindemic’ if COVID-19 and flu cases surge. People may want to reevaluate their self-care routines.”
Lab testing of ClōSYS Ultra Sensitive Oral Rinse against Influenza A H3N2 virus was conducted at Microbac Laboratories, Inc., in Sterling, Virginia, an independent laboratory accredited to test highly infectious viruses.
Lab results from an in vitro laboratory analysis with CloSYS Ultra Sensitive Oral Rinse and Influenza A virus.
Provided by: Microbac Laboratories Inc.